Therapeutic Advances in Infectious Disease

SJR Rank #5,333H-index: 38SJR: 0.948Best quartile: Q2Open AccessAPC: US$2,800Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

SAGE Publications Inc.

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.350.71.051.4

Subject Categories

  • Infectious DiseasesQ2
  • Pharmacology (medical)Q2

Areas: Medicine

Most published research topics

Antifungal resistance and susceptibilityHIV/AIDS Research and InterventionsAntibiotic Use and ResistanceFungal Infections and StudiesTuberculosis Research and EpidemiologyCOVID-19 Clinical Research StudiesHIV/AIDS drug development and treatmentBacterial Identification and Susceptibility TestingAntibiotics Pharmacokinetics and EfficacyAntimicrobial Resistance in Staphylococcus

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs065130195260

Documents per Year

202220250255075100

Detailed Information

ISSN

2049-937X, 2049-9361

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

3.47

References per Document

53.11

Coverage

2013-2026

Scope

Therapeutic Advances in Infectious Disease delivers the highest quality peer-reviewed, open access, original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of infectious diseases. This includes articles examining the social determinants of health. The journal is aimed at an international audience of clinicians, researchers, and students/trainees in infectious disease and related disciplines (including infection control), providing an online forum for rapid dissemination of recent research and perspectives in this area. The journal welcomes unsolicited article proposals. Review articles include expert opinion/perspective, narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, post-marketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses).

Metrics from SCImago Journal Rank 2025. View on SCImago